Scientific commentaries on latest trends and advancements | genOway

Targeted immunotherapy against autoreactive B cells in autoimmune diseases

T-cell engagers in immunotherapies

Our commentaries

Targeted immunotherapy against autoreactive B cells in autoimmune diseases

T-cell engagers in immunotherapies

A radiolabeled VISTA antibody for imaging VISTA expression

hVISTA - antibodies & PET imaging

New CD4-specific minibodies to predict cancer treatment outcomes

CD4 for cancer treatment outcomes

Development of a new antibody-drug conjugate against CD71, INA03, for the treatment of leukemia

TFRC for anti-cancer therapies

HPN328, a new T cell–activating construct for treating solid tumors

CD3ε - T-cell engager assessment

VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response

VISTA - safety and PK profiling

New insights into TNFα aptamers ameliorating inflammation indices in a DTHR humanized TNFα mouse model

Humanized TNFα to study inflammation

BRGSF-HIS: genOway’s mouse model to evaluate the pathogenesis of Staphylococcus aureus Panton-Valentine leukocidin in acute implant-associated osteomyelitis

BRGSF-HIS as model for acute implant-associated osteomyelitis

Development of a new hSIRPα-specific radiotracer for non-invasive PET imaging using genOway’s double humanized genO-hCD47/hSIRPα mouse and genO-MC38-hPD-L1-hCD47-LZ cell line

Targeting the human CD47/SIRPα axis

Myeloid and dendritic cells enhance therapeutics-induced cytokine release syndrome features in humanized BRGSF-HIS preclinical model

CRS in BRGSF-HIS

An engineered humanized common light chain mouse model to develop bispecific antibodies

Humanized cLC model - Bispecific antibody development

A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors

Humanized VISTA mouse & Pharmacokinetics

Targeting myeloid cells in the tumor microenvironment in BRGSF-HIS mice

Myeloid compartment in BRGSF-HIS

Assessing T-cell engagers efficacy in vivo: Versatility of BRGSF-HIS mice

Assess T-cell engager in BRGSF-HIS

CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity

Humanized ICP mouse and cell lines

Expression of druggable myeloid targets in the BRGSF-HIS preclinical model

Myeloid compartment in BRGSF-HIS

An albumin-angiotensin converting enzyme 2-based SARS-CoV-2 decoy with FcRn-driven half-life extension

Humanized HSA/hFcRn mouse

Functional human myeloid compartment in BRGSF-HIS preclinical model

Myeloid compartment in BRGSF-HIS

A new promising family of small molecules regulating the PD-L1/PD-1 signaling pathway

Humanized PD-1/PD-L1 mouse and cell line

Assessing T-cell engagers in vivo: How BRGSF-HIS mice can help

Assess T-cell engager in BRGSF-HIS

Homeostasis of monocytes and lung interstitial macrophages is regulated by collagen domain-binding receptor LAIR1 in vivo

Myeloid compartment in BRGSF-HIS

Challenging the predictability of preclinical models for assessment of T-cell engagers

Assess T-cell engager in BRGSF-HIS

Targeting tumor-associated myeloid cells: The new grail in immuno-oncology?

Myeloid compartment in immuno-oncology

New insights to manage painful neuroma: Study of a nerve graft in rats

Rat models

Humanization of a strategic CD3 epitope enables evaluation of clinical T-cell engagers in a fully immunocompetent in vivo model

T-cell engager CD3

An alternative approach to immunotherapy: A bispecific agonist

Humanized PD-1 & GITR mouse

Relevant preclinical models to test T-cell engagers: The case of CD28

T-cell engager

Tips for choosing the optimal preclinical model: focus on atherosclerosis and LDLR

Rat models

Immunocompromised human serum albumin/human neonatal Fc receptor mouse model: A new xenograft model for efficacy studies of immunotherapies

Therapeutic efficacy and pharmacokinetics

CRISPR-Cas9 effectors facilitate generation of single-sex litters and sex-specific phenotypes

CRISPR/Cas9 technology

The importance of genetic design when choosing your preclinical model: focus on preclinical models for cardiovascular disorders — a case study on BMPR2

Rat models

Immunotherapy efficacy assessment and metastases studies: tHIS model is highly permissive to engraftment

Engraftments in BRGSF-HIS

NOTUM as alternative therapeutic approach to prevent clonal fixation and mutant expansion in patients predisposed to colorectal cancer

Customized mouse model

A human-specific modifier of cortical connectivity and circuit function

Customized mouse model

Predictive in vivo evaluation of immunotherapy efficacy: tHIS is a reliable model

PDX in BRGSF-HIS

Cytokine release syndrome (CRS)

Assess T-cell engager in BRGSF-HIS

When rat models could provide optimized translatability: the case of CD89

Rat models

The importance of genetic design when choosing your preclinical model - A Case Study on GLP-1R

Physiological relevancy in preclinical models

Deciphering high-dose IL-2 toxicity in reconstituted HIS mice

Immunotherapy in BRGSF-HIS

Tumor grafts in preclinical research: Models, models, overall, who is the fittest of them all?

Tumor-graft models

Back to the rat!

Rat models

New doors to potential novel treatments for obesity

Customized mouse model

Uncoupling efficacy from toxicity: a case study on MEDI5752

Bispecific antibodies

Uncoupling toxicity from therapeutic efficacy: a case study on ATOR-1015

Bispecific antibodies

Uncoupling toxicity from therapeutic efficacy: the new challenge of immunotherapies

Assess toxicity with ICP

Degradation tag systems: a good way to SMASh your target (Part 2)

Smash technology

A novel preclinical and translational humanized CD3ε model to study the efficacy of T-cell engagers

T-cell engager

Targeted protein degradation: new promises for “undruggable” diseases (SMASh Part 1)

Smash technology

Define “humanized”: two mouse models helping produce cancer immunotherapies

Humanized mouse models

HSA/hFcRn, a powerful model for your PK/PD studies

Immuno-oncolology models

Part 4: Humanized immune checkpoint mouse models for immuno-oncology studies

Immuno-oncolology models

A Knockin C3-reporter mouse model represents a valuable tool to monitor C3 levels, a biomarker of inflamed versus uninflamed tissues

Customized mouse model

Part 3: BRGSF-HIS, a new human immune system mouse model for immuno-oncology studies

Immuno-oncolology models

Syngeneic mouse models

Customized mouse model

Part 2: BRGSF, a new immunodeficient model for immuno-oncology studies

Immuno-oncolology models

HSC-derived cell fate tracking

Customized mouse model

A VISTA on naive T cell fate

Humanized ICP mouse

Part 1: Toward a better effective preclinical model in immuno-oncology

Immuno-oncolology models

A finely tuned crosstalk between enteric neurons and muscularis macrophages: evidence from a conditional Knockout mouse model developed by genOway

Customized mouse model

Prime Editing: An immature, yet already very exciting new gene editing tool

Prime editing (Cas9-based)

A new Nature report by Bristol-Myers Squibb provides new insights into VISTA biology and design of combination therapies

Humanized ICP in immuno-oncology

FLEx technology and optogenetics: Flipping the switch on gene expression with high spatial and temporal resolution

FLEx technology

6 good reasons to employ our repository Knockout mouse models in your in vivo studies

Eucomm conditional Knockouts

Immune checkpoint inhibitors: A strategy to tackle cancer?

Immuno-oncology models (ICP)

Unexpected genomic rearrangements at targeted loci associated with CRISPR/Cas9-mediated Knockin

CRISPR/Cas9 technology

Improving in vitro models: the coming of age of organoids

Organoids

iPS technology: Four factors that will change the world… some day

iPS technology

CRISPR: A brimming toolbox but no all-in-one

CRISPR technology

No results

Filter

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.